Fund moves
2.1%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EIKN · NASDAQ · Biological Products, (No Diagnostic Substances)
Eikon Therapeutics (EIKN) · oqro.io/stocks/EIKN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.74−0.02 (−0.42%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Eikon Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Eikon Therapeutics (EIKN) was filed with the SEC in the last 90 days.
No trade in Eikon Therapeutics (EIKN) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−68.4% (−$10.26) from Feb 5, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $15.00 on Feb 5, 2026 to $4.74 on Nov 20, 2026 (−68.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Millbrae, Ca.
Last 12 months
Not enough history
Market value
$257M
Short interest: 5.54M shares sold short (10.2% of shares outstanding), −13.1% vs the previous count, 10.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Feb 5, 2026, EIKN is down 68.4% and the index fund is up 1.8%: 70 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much EIKN moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Revenue
—
Free cash flow, last 12 months
−$69.6M
This quarter −$69.6M, a year earlier −$62.1M
Net debt
—
Debt —, cash $98.5M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.
And 16 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
10 certified in FY2026 Q3, vs 8 a year earlier. 10 positions in total, median offered wage $147K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Off-exchange trading: 45.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (28.6% on ATS, 17.0% with other brokers), close to its 26-week average of 44.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (15.6%), INSTINCT X (9.2%), SIGMA X2 (9.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
2 active phase 3 trials and 4 active phase 2 trials led by this company, mostly in advanced solid tumors, nsclc, advanced solid tumor. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Latest annual report filed Mar 30, 2026. Read the filing
84 risk factor headings in this report. There is no earlier annual report to compare it with.
From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
On the public record for Eikon Therapeutics over the 12 months to Nov 21, 2026: 5 clinical trials.